FDA Requested Data on Ibogaine Research

Federal regulators have opened a formal information request regarding ibogaine study designs and safety profiles.

Updated on Oct. 5, 2026 in Substance Abuse

Live Poll

Should federal regulators prioritize research into the potential therapeutic benefits of psychedelic substances?

The FDA issued a request for information on Monday concerning the study design, dosage, and ethical oversight of ibogaine research. The agency aims to better understand the potential benefits and risks of the substance.

Why it matters

Current ibogaine research faces substantial uncertainty regarding its safety profile and therapeutic value. This data gathering effort is intended to address those gaps in the regulatory understanding of the drug.

The FDA proposed a maximum starting dose of 10 mg/kg for research subjects. The request for information specifically excludes comments regarding federal scheduling or decriminalization.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.

President Donald Trump

As the current President of the United States, he previously signed an executive order regarding psychedelics.

The details

The agency is seeking input on small, sequential dose-ascending studies to evaluate the safety and clinical viability of ibogaine. This formal request follows a public hearing on psychedelic therapy and a prior executive order signed by President Donald Trump regarding the field.

October 5, 2026: The FDA released the request for information.
November 20, 2026: Deadline for submitting public comments to the agency.

Deeper Dive

This inquiry follows the framework set by the FDA's July 2026 finalized guidance on psychedelic therapy investigations. The request aligns with the agency's broader movement to standardize research protocols for substances under federal review.

This regulatory step may determine the parameters for future clinical trials, potentially affecting how researchers evaluate the treatment's safety for human patients. It does not change the current legal status or availability of ibogaine for public use.

The takeaway

The FDA is focused on gathering technical and ethical data to clarify the risk profile of ibogaine. Interested stakeholders should note that the agency is strictly avoiding discussions of drug policy reform in this inquiry.